Upstream Bio, Inc.
UPB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002022626
In the last 90 days, Upstream Bio, Inc. insiders filed 0 open-market purchases and 5 sales; 148 institutions reported holding it in 13F filings for Q2 2026, worth $350.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $143.4M (5026.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 11, 2026 | Mar 12, 2025 |
| Revenue | $2.85M | $2.37M |
| Operating expenses | $163.2M | $80.1M |
| Research and development | $136.8M | $63.0M |
| Selling, general and administrative | $26.4M | $17.2M |
| Operating income | -$160.4M | -$77.8M |
| Income tax | $0 | $0 |
| Net income | -$143.4M | -$62.8M |
| EPS, basic | $-2.66 | $-5.58 |
| EPS, diluted | $-2.66 | $-5.58 |
| Weighted shares, basic | 53.9M | 13.7M |
| Weighted shares, diluted | 53.9M | 13.7M |
| Margins and growth | ||
| Operating margin | -5618.8% | -3281.2% |
| Net margin | -5026.0% | -2650.0% |
| Revenue growth, year over year | +20.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 11, 2026 | Mar 12, 2025 |
| Cash and equivalents | $101.6M | $325.9M |
| Short-term investments | $239.9M | $144.6M |
| Accounts receivable | $668.0K | $613.0K |
| Total current assets | $351.8M | $479.2M |
| Property, plant and equipment | $559.0K | $582.0K |
| Goodwill | – | $0 |
| Total assets | $353.8M | $481.7M |
| Accounts payable | $2.73M | $4.04M |
| Total current liabilities | $13.5M | $10.7M |
| Total liabilities | $14.0M | $11.9M |
| Shareholders' equity | $339.8M | $469.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 11, 2026 | Mar 12, 2025 |
| Operating cash flow | -$133.3M | -$59.2M |
| Capital expenditures | $165.0K | $511.0K |
| Free cash flow | -$133.4M | -$59.7M |
| Depreciation and amortization | $188.0K | $89.0K |
| Stock-based compensation | $10.3M | $6.00M |
| Investing cash flow | -$93.5M | -$59.5M |
| Financing cash flow | $2.44M | $418.9M |
| Net change in cash | -$224.3M | $300.3M |
| Ratio | ||
| Stock-based compensation, % of revenue | 362.0% | 253.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.